Viridian Therapeutics, Inc. (LON:0K1R)
28.63
-1.62 (-5.36%)
Feb 12, 2026, 4:19 PM GMT
Viridian Therapeutics Employees
Viridian Therapeutics had 143 employees as of December 31, 2024. The number of employees increased by 49 or 52.13% compared to the previous year.
Employees
143
Change (1Y)
49
Growth (1Y)
52.13%
Revenue / Employee
368.27K GBP
Profits / Employee
-1.28M GBP
Market Cap
2.10B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 143 | 49 | 52.13% | 143 | 0 |
| Dec 31, 2023 | 94 | 8 | 9.30% | 94 | 0 |
| Dec 31, 2022 | 86 | 36 | 72.00% | 86 | 0 |
| Dec 31, 2021 | 50 | 23 | 85.19% | 50 | 0 |
| Dec 31, 2020 | 27 | -19 | -41.30% | 26 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Genus | 3,190 |
| Oxford Nanopore Technologies | 1,325 |
| Oxford Biomedica | 900 |
| hVIVO | 301 |
| Avacta Group | 151 |
| 4basebio | 110 |
| Scancell Holdings | 60 |
| PureTech Health | 56 |
Viridian Therapeutics News
- 9 days ago - Viridian Therapeutics (VRDN) Receives Updated Analyst Rating from Wells Fargo | VRDN Stock News - GuruFocus
- 17 days ago - Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) - Seeking Alpha
- 5 weeks ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - VRDN: UBS Initiates Coverage with a 'Buy' Rating and $50 Price Target | VRDN Stock News - GuruFocus
- 5 weeks ago - Viridian Therapeutics Prepares for Transformational 2026 - Benzinga
- 5 weeks ago - Viridian Therapeutics Prepares for Transformational 2026 - Business Wire
- 5 weeks ago - Insider Sell: Jennifer Tousignant Sells 2,272 Shares of Viridian Therapeutics Inc (VRDN) - GuruFocus
- 7 weeks ago - FDA Accepts Viridian's Veligrotug BLA For Priority Review In Thyroid Eye Disease - Nasdaq